These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15012575)

  • 21. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery.
    Reuben SS; Connelly NR
    Anesth Analg; 2000 Nov; 91(5):1221-5. PubMed ID: 11049912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
    Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM;
    Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A; Williams GW; McKenna F; Fort JG
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decisions loom on selective COX-2 inhibitors.
    Miller JL
    Am J Health Syst Pharm; 1999 Jan; 56(2):106-7. PubMed ID: 10030522
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
    Whelton A; White WB; Bello AE; Puma JA; Fort JG;
    Am J Cardiol; 2002 Nov; 90(9):959-63. PubMed ID: 12398962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wooltorton E
    CMAJ; 2002 Jun; 166(13):1692-3. PubMed ID: 12126328
    [No Abstract]   [Full Text] [Related]  

  • 32. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 33. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early trials probe COX-2 inhibitors' cancer-fighting potential.
    Ziegler J
    J Natl Cancer Inst; 1999 Jul; 91(14):1186-7. PubMed ID: 10413412
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.
    Malmstrom K; Daniels S; Kotey P; Seidenberg BC; Desjardins PJ
    Clin Ther; 1999 Oct; 21(10):1653-63. PubMed ID: 10566562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective COX-2 inhibitors.
    Pasero C; McCaffery M
    Am J Nurs; 2001 Apr; 101(4):55-6. PubMed ID: 11301685
    [No Abstract]   [Full Text] [Related]  

  • 38. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COX-2 inhibitors still eyed for cancer prevention.
    Thompson CA
    Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
    [No Abstract]   [Full Text] [Related]  

  • 40. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.